The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …

Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in
clinical stage III nodal melanoma, and pathologic response is strongly associated with …

Even though the immuno-oncology (IO) era has achieved many successes, some signs of
research development deceleration are arising. Recently, the number of FDA …

PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–
small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a …

Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …

Highlights•A melanoma consensus conference, organised by the ESMO Guidelines
Committee, was attended by 32 experts from 14 countries•The experts compiled …

PURPOSE To analyze long-term outcomes after treatment discontinuation of anti–
programmed death-1 (anti–PD-1) therapy in a cohort of patients with melanoma with the …

Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which inhibit PD-1,
have greatly improved survival for many patients with cancer, but are prohibitively expensive …

Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients,
however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to …